" class="no-js "lang="en-US"> Daewoong Pharmaceutical Archives - Medtech Alert
Friday, June 09, 2023

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease

HanAll Biopharma and Daewoong Pharmaceutical announced that they have entered into a co-development agreement with NurrOn […]

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes

The research results of a Daewoong Pharmaceutical SGLT-2 inhibitor new drug for diabetes, ‘Envlo’, have been […]

Daewoong Pharmaceutical Begins the First Administration of the Bersiporocin, a New Treatment for Idiopathic Pulmonary Fibrosis

The world’s first-in-class candidate substance against idiopathic pulmonary fibrosis, ‘Bersiposocin‘ (DWN12088), which is under the […]

Daewoong Pharmaceutical Submitted NDA for its Global New Drug Fexuclue in 11 Countries

Fexuclue from Daewoong Pharmaceutical is attracting attention as a game changer in the global gastroesophageal […]

  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more